← Back to Analyst Consensus 
BDTX Buy
Black Diamond Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 14
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 9, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Apr 29, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Mar 17, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Jan 16, 2026 | Piper Sandler | maintain | Overweight → Overweight | $8 | 54% |
| Dec 4, 2025 | Guggenheim | downgrade | Buy → Neutral | $0 | 52% |
| Oct 1, 2025 | Freedom Broker | initiate | — → Buy | — | 59% |
| Sep 4, 2025 | Guggenheim | initiate | — → Buy | $8 | 52% |
| Aug 11, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $10 | 44% |
| Mar 18, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $12 | 44% |
| Mar 7, 2025 | Stifel | maintain | Buy → Buy | $15 | 53% |
| Nov 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Oct 9, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Oct 8, 2024 | Wedbush | reiterate | Outperform → Outperform | $16 | 58% |
| Sep 24, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Sep 23, 2024 | Piper Sandler | maintain | Overweight → Overweight | $15 | 54% |
| Sep 18, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Sep 10, 2024 | Wedbush | reiterate | Outperform → Outperform | $16 | 58% |
| Sep 4, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Aug 7, 2024 | Wedbush | reiterate | Outperform → Outperform | $16 | 58% |
| Jul 31, 2024 | Raymond James | initiate | — → Outperform | $20 | 54% |
| Jul 3, 2024 | Piper Sandler | maintain | Overweight → Overweight | $12 | 54% |
| Jun 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| May 16, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $11 | 44% |
| Apr 8, 2024 | Wedbush | maintain | Outperform → Outperform | $16 | 58% |
| Mar 18, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $12 | 44% |
| Mar 13, 2024 | Wedbush | reiterate | Outperform → Outperform | $10 | 58% |
| Nov 22, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| Sep 12, 2023 | Wedbush | reiterate | Outperform → Outperform | $10 | 58% |
| Jul 14, 2023 | Piper Sandler | initiate | — → Overweight | $11 | 54% |
| Jun 30, 2023 | Stifel | upgrade | Hold → Buy | $10 | 53% |
| Jun 28, 2023 | HC Wainwright & Co. | upgrade | Neutral → Buy | $11 | 44% |
| Jun 27, 2023 | Stifel | reiterate | Hold → Hold | $2 | 53% |
| Jun 27, 2023 | Wedbush | upgrade | Neutral → Outperform | $10 | 58% |
| May 10, 2023 | Wedbush | reiterate | — → Neutral | $3 | 58% |
| Mar 29, 2022 | Wedbush | downgrade | Outperform → Neutral | $0 | 58% |
| Mar 22, 2022 | HC Wainwright & Co. | downgrade | Buy → Neutral | $0 | 44% |
| Mar 18, 2022 | Stifel | maintain | — → Hold | $4 | 53% |
| Sep 30, 2021 | Stifel | initiate | — → Hold | $10 | 53% |
| Jan 7, 2021 | Wedbush | initiate | — → Outperform | $0 | 58% |
| Nov 24, 2020 | Berenberg | initiate | — → Buy | $58 | 29% |
| May 4, 2020 | HC Wainwright & Co. | initiate | — → Buy | $53 | 44% |
| Feb 24, 2020 | Jefferies | initiate | — → Buy | $47 | 52% |
| Feb 24, 2020 | Canaccord Genuity | initiate | — → Buy | $50 | 48% |
| Feb 24, 2020 | Cowen & Co. | initiate | — → Outperform | $0 | — |
| Feb 24, 2020 | JP Morgan | initiate | — → Overweight | $42 | 55% |
Price Target Trend
Apr 21, 2026 Oct 26, 2026
EPS Estimates
+1q —
0q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days